J2T-MC-KGBG Protocol (b) 
 
A Phase 1, Open- Label, Single -Dose Bioequivalence Study of Injections of Lebrikizumab Using 
a 2-mL Pre -Filled Syringe with Needle Safety Device and an Investigational 2- mL Autoinjector 
in Healthy Participants  
 
[STUDY_ID_REMOVED] 
 Approval Date: 17 -Aug-2021 
CONFIDENTIAL  J2T-MC-KGBG (b) 
 1 Title Page  
Confidential Information  
The information contained in this document is confidential and is intended for the use of clinical investigators.  It is the property of 
Eli Lilly and Company or its subsidiaries and should not be copi[INVESTIGATOR_762333]  (LY3650150 ), unless such persons are bound by a confidentiality agreement with Eli Lilly and 
Company or its sub sidiaries.  
 
Note to Regulatory Authorities:  This document may contain protected personal data and/or commercially confidential information 
exempt from public disclosure.  Eli Lilly and Company requests consultation regarding release/redaction prior to any  public release.  
In the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries . 
 
Protocol Title : A Phase 1, Open -Label, Single -Dose  Bioequivalence Study of Injections of 
Lebrikizumab Using a 2-mL Pre-Filled Syringe  with Needle Safety Device and 
an Investigational 2-mL Autoinjector  in Healthy Participants  
Protocol Number:  J2T-MC-KGBG  
Amendment Number: b 
Compoun d: Lebrikizumab (LY3650150)  
Study Phase: 1 
Short Title:  A Bioequivalence Study of Lebrikizumab Using a Pre-Filled Syringe  with Needle 
Safety Device and an Investigational Autoinjector in Healthy Participants  
Sponsor Name:  [CONTACT_11028]:  Indianapolis, Indiana , [LOCATION_003] [ZIP_CODE]  
Regulatory Agency Identifier Number(s) : IND: 119866  
Document ID: VV-CLIN -002582   
 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 [ADDRESS_1044275] Infor mation will be provided separately . 
  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 3 Protocol Amendment Summary of Changes Table  
 
DOCUMENT HISTORY  
Document  Date  
Protocol  J2T-MC-KGBG  04 Mar ch 2021  
Amendment (a)  19 May 2021  
Amendment (b)  
Overall Rationale for the Amendment:  
This protocol has been a mended in response to  comment from study site  to provide clarification 
regarding  procedures i n section on Preparation/Handling/Storage/ accountability . Minor editorial 
changes have  been done  which is not reflected in the below table . The following table describes 
the change made in amendment (b). 
Section # and Name  [CONTACT_11029]  
6.2. Preparation / 
Handling / 
Storage /accountability    The following statement is 
removed . 
The investigator or designee will 
return all used and unused AI 
devices to Lilly or its designee at 
the end of the study .  The device group no longer 
requests sites to return used 
and unused devices to Lilly.  
  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 4 Table of Contents  
1. Protocol Summary  ................................ ................................ ................................ .......... 7 
1.1. Synopsis  ................................ ................................ ................................ ............................ 7 
1.2. Schema  ................................ ................................ ................................ .............................. 8 
1.3. Schedule of Activities (SoA)  ................................ ................................ ............................ 9 
2. Introduction  ................................ ................................ ................................ ................... 13 
2.1. Study Rationale  ................................ ................................ ................................ ............... 13 
2.2. Background  ................................ ................................ ................................ ..................... 13 
2.3. Benefit/Risk Assessment  ................................ ................................ ................................ 14 
3. Objectives and Endpoints  ................................ ................................ ............................ 16 
4. Study Design  ................................ ................................ ................................ .................. 17 
4.1. Overall Desig n ................................ ................................ ................................ ................ 17 
4.2. Scientific Rationale for Study Design  ................................ ................................ ............ 18 
4.3. Justification for Dose  ................................ ................................ ................................ ......19 
4.4. End of Study Definition  ................................ ................................ ................................ ..19 
5. Study Population  ................................ ................................ ................................ ........... 20 
5.1. Inclusion Criteria  ................................ ................................ ................................ ............ 20 
5.2. Exclu sion Criteria  ................................ ................................ ................................ ........... 21 
5.3. Lifestyle Considerations  ................................ ................................ ................................ .24 
5.3.1.  Meals and Dietary Restrictions  ................................ ................................ ....................... 24 
5.3.2.  Caffeine, Alcohol, and Tobacco  ................................ ................................ ..................... 24 
5.3.3.  Activity  ................................ ................................ ................................ ........................... 24 
5.4. Screen Failures  ................................ ................................ ................................ ................ 24 
6. Study Intervention  ................................ ................................ ................................ ........ 25 
6.1. Study Interventions Administered  ................................ ................................ .................. 25 
6.1.1.  Medical Devices ................................ ................................ ................................ .............. 25 
6.2. Preparation/Handling/Storage/Accountability  ................................ ................................ 25 
6.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ............ 26 
6.4. Study Intervention Compliance  ................................ ................................ ...................... 26 
6.5. Concomitant Therapy  ................................ ................................ ................................ .....26 
6.6. Dose Modification  ................................ ................................ ................................ .......... 27 
6.7. Intervention after the End of the Study  ................................ ................................ ........... 27 
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ................................ ................................ ........................ 28 
7.1. Discontinuation of Study Intervention  ................................ ................................ ............ 28 
7.2. Participant Discontinuation/Withdrawal from the Study  ................................ ................ [ADDRESS_1044276] to Follow -up................................ ................................ ................................ ............ 28 
8. Study Assessments and Procedures ................................ ................................ ............. 30 
8.1. Efficacy Assessments  ................................ ................................ ................................ .....30 
8.2. Safety Assessments  ................................ ................................ ................................ ......... 30 
8.2.1.  Physical Examinations  ................................ ................................ ................................ ....30 
8.2.2.  Vital Signs  ................................ ................................ ................................ ....................... 31 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 [ADDRESS_1044277]  ................................ ................................ ................. 36 
8.4. Treatment of Overdose  ................................ ................................ ................................ ...37 
8.5. Pharmacokinetics  ................................ ................................ ................................ ............ 37 
8.5.1.  Bioan alysis  ................................ ................................ ................................ ...................... 37 
8.6. Pharmacodynamics  ................................ ................................ ................................ ......... 37 
8.7. Genetics  ................................ ................................ ................................ .......................... 37 
8.8. Biomarkers  ................................ ................................ ................................ ...................... 38 
8.9. Immunogenicity Assessments ................................ ................................ ......................... 38 
8.10.  Health Economics  ................................ ................................ ................................ ........... 38 
9. Statistical Considerations  ................................ ................................ ............................. 39 
9.1. Statistical Hypotheses  ................................ ................................ ................................ .....39 
9.2. Sample Size Determination  ................................ ................................ ............................ 39 
9.3. Populations for Analyses  ................................ ................................ ................................ 39 
9.4. Statistical Analyses  ................................ ................................ ................................ ......... 39 
9.4.1.  General Considerations  ................................ ................................ ................................ ...39 
9.4.2. Pharmacokinetic Analyses  ................................ ................................ .............................. 40 
9.4.3.  Safety Analyses  ................................ ................................ ................................ ............... 40 
9.4.4.  Evaluation of Immunogenicity  ................................ ................................ ....................... 40 
9.5. Interim Analyses  ................................ ................................ ................................ ............. 41 
9.6. Data Monitoring Committee (DMC)  ................................ ................................ .............. 41 
10. Supporting Documentation and Operational Considerations  ................................ ..42 
10.1.  Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  ................................ ................................ ................................ ................ 42 
10.1.1.  Regulatory and Ethical Considerations  ................................ ................................ ........... 42 
10.1.2.  Informed Consent Process  ................................ ................................ .............................. 42 
10.1.3.  Data Protection ................................ ................................ ................................ ................ 43 
10.1.4.  Dissemination of Clinical Study Data ................................ ................................ ............. 43 
10.1.5.  Data Quality Assurance  ................................ ................................ ................................ ..44 
10.1.6.  Source Documents  ................................ ................................ ................................ .......... 45 
10.1.7.  Study and Site Start and Closure  ................................ ................................ .................... 45 
10.1.8.  Publication Policy  ................................ ................................ ................................ ........... 46 
10.2.  Appendix 2: Clinical Laboratory Tests  ................................ ................................ ........... 47 
10.2.1.  Blood Sampling Summa ry ................................ ................................ .............................. 49 
10.3.  Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  ................................ ......................... 50 
10.3.1.  Definition of AEs and ADE  ................................ ................................ ............................ 50 
10.3.2.  Definition of SAE, SADE, and UADE  ................................ ................................ ........... 51 
10.3.3.  Recording and Follow -Up of AE and/or SAE  ................................ ................................ 52 
10.3.4.  Reporting of SAEs  ................................ ................................ ................................ .......... 54 
10.3.5.  Regulatory Reporting Requirements  ................................ ................................ ............... 54 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 6 10.4.  Appendix 4: Contraceptive Guidance and Collection of  
Pregnancy Information  ................................ ................................ ................................ ...56 
10.5.  Appendix 5: Genetics ................................ ................................ ................................ ......60 
10.6.  Appendix 6: Liver Safety: Suggested Actions and Follow -up 
Assessments  ................................ ................................ ................................ .................... 61 
10.7.  Appendix 7: Recommended Laboratory Testing for 
Hypersensitivity Events  ................................ ................................ ................................ ..63 
10.8.  Appendix 8: Medical Device Adverse Events (AEs), Adverse 
Device Effects (ADEs), Serious Adverse Events (SAEs) and 
Device Deficiencies: Definition and Procedures for Recording, 
Evaluating, Follow -up, and Reporting  ................................ ................................ ............ 65 
10.9.  Appendix 9: Abbreviations  ................................ ................................ ............................. 66 
10.10.  Appendix 10: Protocol Amendment History  ................................ ................................ ..69 
11. References  ................................ ................................ ................................ ...................... 70 
 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 7 1. Protocol Summary  
1.1. Synopsis  
Protocol Title:  A Phase 1, Open -Label, Single -Dose  Bioequivalence Study of Injections of 
Lebrikizumab Using a 2-mL Pre-Filled Syringe  with Needle Safety Device and an 
Investigational 2-mL Autoinjector in Healthy Participants  
Short Title:  A Bioequivalence Study of Lebrikizumab Using a Pre-Filled Syringe  with Needle 
Safety Device and an Investigational Autoinjector in Healthy Participants  
Rationale : Study J2T-MC-KGBG (KGBG ) will assess the PK, safety , and tolerability of a 
250-mg SC dose of lebrikizumab ( LY3650150 ) solution formulation  administered using a  2-mL 
PFS-NSD  or an investigational 2-mL AI. Both devices will be evaluated at 3 different injection 
sites (arm, thigh, and abdomen) to expand the options for administration in patient use. Both the 
PFS-NSD and the AI are planned for use to administer lebrikizumab in subsequent studies and 
patien t use.  
Objectives and Endpoint s 
Objectives  Endpoints  
Primary   
To evaluate the PK of lebrikizumab after SC 
administration of 250-mg dose using a 2-mL 
PFS-NSD  and a  2-mL AI in healthy 
participants  • Cmax 
• AUC(0 -∞) 
• AUC([ADDRESS_1044278]) 
Secondary   
To describe  the safety and tolerability of 
lebrikizuma b 250 -mg dose through  SC in 
healthy participants  Number and incidence of   
• SAEs  
• TEAEs  
Abbreviations: AI = autoinjector; AUC(0 -∞) = area under the concentration versus time curve from time zero to 
infinity; AUC([ADDRESS_1044279]) = area under the concentration versus time curve from time zero to time t, where t is the last 
time point with a measurable concentration; C max = maximum observed drug concentration; PF S-
NSD  = pre-filled syrin ge with needle safety device ; PK = pharmacokinetics; SAE = serious adverse event; 
SC = subcutaneous; TEAE  = treatment -emergent adverse event .  
Overall Design  
Study KGBG  is a Phase 1, multi -site, randomized, parallel -design, open -label, 2 -arm, single -
dose study of lebrikizumab in healthy participants . 
Disclosure Statement : This is an open -label, parallel -group bioequivalence  study with  2 arms . 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 8 Number of Participant s: 
Approximately 240 participants may  be enrolled so that approximately 216 participants  (108 in 
the PFS-NSD  group and 108 in the AI group ) complete the study . 
Intervention Groups  and Duration : 
All participants will be screened within 28 days prior to enrollment . A single dose of 
lebrikizumab will be administered SC through either PFS-NSD  or AI into the arm, thigh, or 
abdomen  on Day  1 and participants will be followed through Day 99. 
Data Monitoring Committee: No 
1.2. Schema  
Not applicable.  
 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 9 1.3. Schedule of Activities  (SoA)  
Study Schedule Protocol J2T-MC-KGBG  
 Screening  Study Day  Comments  
Procedure  -28 to -2 
days prior 
to Day 1  -1 1 3 5 
±1d 8 
±1d 11 
±1d 15 
±2d 22 
±2d 29 
±2d 36 
±2d 43 
±2d 50 
±2d 57 
±2d 64 
±2d 71 
±3d 85 
±3d 99 
±3d 
or 
ED  
Informed consent  X                   
Medical history and 
demographics  X                   
Review and confirm 
inclusion and 
exclusion criteria  X X                  
Admission to CRU   X                  
Discharge from 
CRU  
  X                Participants may be 
discharged after 
completing the scheduled 
activities  on Day 1,  or 
later at the investigator’s 
discretion.  
Outpatient visit  X   X X X X X X X  X  X  X X X  
Safety assessment 
(telephone call)            X  X  X    To check on the presence 
of any AEs and 
concomitant medications.  
Randomization    X                Participant s will be 
random ly ass igned 1:1 to 
1 of 2  delivery devices  
and 1:1:1 to 1 of 3 
injection locations per 
delivery device . 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 10  Screening  Study Day  Comments  
Procedure  -28 to -2 
days prior 
to Day 1  -1 1 3 5 
±1d 8 
±1d 11 
±1d 15 
±2d 22 
±2d 29 
±2d 36 
±2d 43 
±2d 50 
±2d 57 
±2d 64 
±2d 71 
±3d 85 
±3d 99 
±3d 
or 
ED  
Height, weight, and 
BMI  
X X                X Participant weight at Day 
-1 will be used for weight 
category stratification at 
randomization. Weight , 
but not height,  will be 
measured on Day -1, and 
Day 99 or ED. 
Physical 
examination  
X X                X Full physical examination  
at screening or at Day -1. 
Symptom -directed 
examinations at other 
times, and as deemed 
necessary by [CONTACT_1275].  
Vital signs (pulse 
rate and blood 
pressure) (sitting) , 
and body 
temperature  X X P,  
3hr     X    X      X Predose Day 1 conducted 
within 2 hours predose . 
Postdose assessment 3  ± 
1 hour. Time points may 
be added if warranted at 
the discretion of the 
investigator.  
Clinical laboratory 
tests 
X X P X    X  X        X Day 1 conducted  within 2 
hours predose. See 
Section  10.2 Appendix  2, 
Clinical Laboratory Tests, 
for details.   
Serology  
X                  See Section 10.2 
Appendix  2, Clinical 
Laboratory Tests, for 
details.  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 11  Screening  Study Day  Comments  
Procedure  -28 to -2 
days prior 
to Day 1  -1 1 3 5 
±1d 8 
±1d 11 
±1d 15 
±2d 22 
±2d 29 
±2d 36 
±2d 43 
±2d 50 
±2d 57 
±2d 64 
±2d 71 
±3d 85 
±3d 99 
±3d 
or 
ED  
QuantiFERON ®-T
B Gold test  X                   
Ethanol test and 
drug screen  X X                 Tests may be repeated at 
additional time points at 
the discretion of the 
investigator.  
FSH (females only)  X                  See Section 10.4, 
Appendix  4.  
Pregnancy test  
(females of 
childbearing 
potential only)  X X                X Serum pregnancy test will 
be performed at screening 
and Day -1. Urine 
pregnancy test  will be 
performed at Day  99 or 
ED. See Section 10.4, 
Appendix  4.  
Single 12 -lead ECG 
(supi[INVESTIGATOR_050])  X X                X May be obtained at 
additional times , when 
deemed clinically 
necessary.  
Lebr ikizumab 
administration 
(1 injection per 
dose)    X                See Section  6.1.  
 
Lebr ikizumab PK 
sample    P X X X X X X X  X  X  X X X Day 1: collected  within 2 
hours predose.  
Immunogenicity 
sample    P     X  X        X Day 1: collected  within 2 
hours predose.  
Pharmacogenetic 
sample    P                Day 1: collected  within 2 
hours predose.  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 12  Screening  Study Day  Comments  
Procedure  -28 to -2 
days prior 
to Day 1  -1 1 3 5 
±1d 8 
±1d 11 
±1d 15 
±2d 22 
±2d 29 
±2d 36 
±2d 43 
±2d 50 
±2d 57 
±2d 64 
±2d 71 
±3d 85 
±3d 99 
±3d 
or 
ED  
AE, product 
complaints , and 
concomitant 
medication  X X X X X X X X X X X X X X X X X X If an AE of ISR is 
reported , see Section 
[IP_ADDRESS] .  
Abbreviations: AE = adverse event; BMI = body mass index; CRU = clinical research unit; d  = day; ECG = electrocardiogram; ED  = early discontinuation; 
FSH = follicle -stimulating hormone; ISR = injection -site reaction; P = pre-dose; PK  = pharmacokinetic s; TB = tuberculosis.   
 
 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 13 2. Introduction  
2.1. Study Rationale  
Study J2T-MC-KGBG  (KGBG ) will assess the PK, safety , and tolerability of a 250-mg SC dose 
of lebrikizumab ( LY3650150 ) solution formulation  administered using a  2-mL PFS-NSD  or an 
investig ational 2-mL AI. Both devices will be evaluated at 3 different injection sites (arm, thigh, 
and abdomen) to expand the options for administration in patient use. Both the PFS-NSD and the 
AI are planned for use to administer lebrikizumab in subsequent studies and patient use.  
2.2. Background  
Lebrikizumab (LY3650150) is a humanized monoclonal antibody  based on the human 
immunoglobulin G4  antibody stabilized by a mutated Fc region. Lebrikizumab binds specifically 
to soluble IL -13 and blocks IL -13 signaling through the IL-4 receptor alpha /IL-[ADDRESS_1044280], thereby [CONTACT_762339] -13 with high pote ncy. 
Lebrikizumab has been investigated for the treatment of AD, asthma, chronic obstructive 
pulmonary disease , idiopathic pulmonary fibrosis , and refractory Hodgkin lymphoma . Currently , 
lebrikizumab is being actively developed for the treatment of AD. 
A detailed description of the chemistry, pharmacology, efficacy, and safety of lebrikizumab  is 
provided in the Investigator’s Brochure.  
Safety summary  
As of the  Investigator’s Brochure cutoff date of [ADDRESS_1044281] 1 dose of lebrikizumab.  Safety 
information provided  in the Investigator’s Brochure  is summarized here.  
Healthy participants  
Lebrikizumab has been evaluated in 5 healthy participant studies. Single IV doses included 0.1, 
0.3, 1.0, 3.0, and 5.0 mg/kg . Doses administered SC includ ed a dose at 1 mg/kg, and single doses 
including  37.5, 125, 250, and 375 mg . 
Five treatment -emergent SAEs were reported in lebrikizumab -treated participants. All events 
were assessed by [CONTACT_143210]. No SAE PT was reported  in more 
than 1 participant.  No deaths were reported in healthy participant studies.  Administration of a 
single dose of lebrikizumab  in healthy participant  studies  was well tolerated . 
Patients  
Lebrikizumab has been evaluated in 686 patients with AD, 3321 patients with asthma, and 477 
patients with other indications.   
Studies in patients with AD  
In Phase 2 studies , the doses administer ed were 125, 250, and 500 mg.  In Phase 3 studies, the 
dose was 250 mg administered every 2 or 4 weeks.  One death from myocardial infarction has 
been reported in the ongoing Phase 3 study and was assessed as not related by [CONTACT_093]. 
This death was reported after the Investigator’s Brochure cutoff date of 22 September 2020 . 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 14 In the  3 completed Phase 2 studies  
• A low frequency of SAEs were reported in the lebrikizumab -treated groups and placebo 
or topi[INVESTIGATOR_762334].  
• No PT was reported in more than 1 patient.  
• A majority of SAEs were assessed by [CONTACT_762340].  
• A similar proportion of patients in each treatment group reported AEs leading to study 
discontinuation.  
Studies in patients with asthma  
In Phase 2 studies , doses included 37.5, 125, or 250 mg every 4 weeks, and in some studies 
patients were dosed at 0.3 mg/kg to 5 mg/kg.  In Phase 3, doses studied included 37.5 or 125 
administered once every 4 weeks.  Six deaths were reported in these s tudies . 
In the 3 completed Phase 3 studies of adult patients  
• A similar proportion of patients in all treatment groups had at least 1 SAE.  
• In both treatment groups, the most commonly reported SAE was the PT asthma.   
• A similar proportion of pat ients in each treatment group reported AEs leading to study 
discontinuation.  
Studies in patients with chronic obstructive pulmonary disease , idiopathic pulmonary fibrosis , or 
Hodgkin lymphoma  
In one Phase 2 study  of patients with chronic obstructive pulmonary disease , the dose was 
125 mg administered once every 4 weeks.  Three  deaths were reported  in this study , all assessed 
as not related  to study drug . In one Phase 2 study  of patients with idiopathic pulmonary fibrosis , 
the dose was 250 mg administered once every 4 weeks.  Forty -eight  deaths were reported  in this 
study , the majority of which were due to progression of disease . In one Phase 1/2 study  of 
patients with Hodgkin lymphoma , doses from 0.1 to 10.0 mg/kg were administered intravenousl y 
every 2 weeks for a maximum of 24 weeks . Nine  deaths were reported  in this study , all of which 
were due to disease progression . 
Overall, the safety findings i n the lebrikizumab groups were similar to the placebo or comparator 
groups across these clinical studies. There were no significant trends observed in the  
treatment -emergent adverse event s reported between the treatment groups in all 3 indications.  
Anti -lebrikizumab antibodies  
In the completed studies of patients with AD, 12.3% to 24.5% of patients developed ADA s. In 
general, the presence of anti -lebrikizumab antibodies had no appar ent impact on PK results, and 
overall there was no relationship between anti -lebrikizumab antibody status and efficacy or 
safety events.  
2.3. Benefit/Risk Assessment  
Risk from i mmunomodulatory  therapy  
As an immunomodulatory therapy , lebrikizumab  may increase the risk of developi[INVESTIGATOR_61489].  In patients with moderate -to-severe AD in the 
lebrikizumab program, the most commonly reported infections include nasopharyngitis and 
Approved on 17 Aug 2021 GMT
C O N FI D E N TI A L  J 2 T -M C -K G B G (b) 
 [ADDRESS_1044282] u dies . I m m u n o m o d ulat or y t hera pi[INVESTIGATOR_66488] y i ncreas e t he ris k of 
mali g na n cies; h o we ver, d ue t o t he si n gle d os e of le bri kiz u ma b bei n g a d mi nistere d i n t his st u d y, 
it is n ot c o nsi dere d necessar y t o m o nit or f or s uc h effects.  
H y perse nsiti vit y re acti o ns  
T here w ere n o re p ort e d h y p erse nsiti vit y e v e nts i n t he P hase [ADDRESS_1044283] u d y . H o we ver, 
partici pa nts ma y be n efit fr o m t he scree ni n g pr oce d ures (t hr o u g h det ecti o n of u n k n o w n healt h 
iss ues) e ve n if t he y recei ve n o t hera p e utic be nefit fr o m t he st u d y . 
M ore detaile d i nf or mati o n a b o ut t he k n o w n a n d e x pecte d b e nefits a n d ris ks a n d reas o n a bl y 
e x pecte d  A E s of le bri kiz u ma b ma y b e  f o u n d i n t h e I n vesti gat or’s Br oc h ure  as well as reas o na bl y 
a ntici pate d A D E s f o u n d i n t he AI  I n vesti gat or’s Br oc h ure . 
  
A p pr o ve d o n 1 7 A u g 2 0 2 1 G M T 
CONFIDENTIAL  J2T-MC-KGBG (b) 
 16 3. Objectives  and Endpoints  
Objectives  Endpoints  
Primary   
To evaluate the PK of lebrikizumab after SC 
administration o f 250-mg dose using a 2-mL 
PFS-NSD  and a 2-mL AI in healthy 
participants  • Cmax 
• AUC(0 -∞) 
• AUC([ADDRESS_1044284]) 
Secondary   
To describe  the safety and tolerability of 
lebrikizuma b 250-mg dose through  SC in 
healthy participants  Number and incidence of  
• SAEs  
• TEAEs  
Tertiary/Exploratory   
• To evaluate the potential development 
of anti -lebrikizumab antibodies  
• To evaluate the impact of injection -
site location on PK  • TE-ADA  
 
• Cmax 
• AUC(0 -∞) 
• AUC([ADDRESS_1044285]) 
Abbreviations: AI = autoinjector; AUC(0 -∞) = area under the concentration versus time curve from time zero to 
infinity; AUC([ADDRESS_1044286]) = area under the concentration versus time curve from time zero to time t, where t is the last 
time point with a measurable  concentration; C max = maximum observed drug concentration; PF S-
NSD  = pre-filled syringe  with needle safety device ; PK = pharmacokinetics; SAE = serious adverse event; 
SC = subcutaneous; TE-ADA  = treatment -emergent antidrug antibod y; TEAE  = treatment -emerg ent adverse 
event . 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 17 4. Study Design  
4.1. Overall  Design  
Study KGBG  is a Phase 1, multi -site, randomized, parallel -design,  open -label, 2 -arm, single -
dose study in healthy participants . 
Infection risk 
Participants should follow local guidance and CRU precautions to minimize risk for COVID -19 
infection.  
Screening  
All participants will be screened within 28 days prior to enrollment . At screening, participants 
will be stratified into 1 of 3 weight categori es.  
• less than 70 .0 kg,  
• 70.0 to 80 .0 kg, and  
• more than 80 .0 kg. 
Study participants  
Approximately 240 participants will be random ly ass igned according to Table  KGBG. 1, so that 
approximately 216 participants complete the study. If a participant needs to be replaced, a 
participant of the same weight category will be selected as their replacement.  
Treatment and assessment period  
Eligible participants will be admitted to the CRU on Day -1. Participants will be stratified  into 1 
of 3 weight categories based on their Day -1 weight . 
Within th e 3 weight categories, participants will be random ly ass igned (Table  KGBG. 1) using a 
computer -generated allocation code (Section  6.3): 
• 1:1 to delivery device (either PFS -NSD  [reference] or AI [test])  
• within each delivery -device group 1:1:1  to injection site (arm, thigh, or abdomen)  
On Day 1, participant s will receive a 2-mL ( total 250 mg lebrikizumab) SC dose , administered  
by [CONTACT_1719],  and delivered via the device and in the location assigned by [CONTACT_101148] .  
Participants may be allowed to leave the CRU after completing the 3(±1) -hour safety 
assessments on Day 1, or later at the investigator’s discretion . Participants  will return for PK and 
immunogenicity sampling and safety assessments at predefined times up to [ADDRESS_1044287] of telephone 
assessment.  
Safety and tolerability will be assessed through clinical laboratory tests, vital sign measurements, 
recording of AEs, physical examination, and immunogenicity . 
 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 18 Table  KGBG. 1. Study KGBG Stratification and Randomization Plan  
Weight Category  
(Desired Number of 
Participants)  Injection Device  Subcutaneous Injection 
Location  Desired Number 
of Participant s 
Low 
<70.0 kg 
 
(72 participants)  2-mL PFS -NSD  (Reference)  Arm 12 
2-mL AI (Test)  12 
2-mL PFS -NSD  (Reference)  Abdomen  12 
2-mL AI (Test)  12 
2-mL PFS -NSD  (Reference)  Thigh  12 
2-mL AI (Test)  12 
Medium  
70.0 – 80.0 kg 
 
(72 participants)  2-mL PFS -NSD  (Reference)  Arm 12 
2-mL AI (Test)  12 
2-mL PFS -NSD  (Reference)  Abdomen  12 
2-mL AI (Test)  12 
2-mL PFS -NSD  (Reference)  Thigh  12 
2-mL AI (Test)  12 
High  
>80.0 kg 
 
(72 participants)  2-mL PFS -NSD  (Reference)  Arm 12 
2-mL AI (Test)  12 
2-mL PFS -NSD  (Reference)  Abdomen  12 
2-mL AI (Test)  12 
2-mL PFS -NSD  (Reference)  Thigh  12 
2-mL AI (Test)  12 
Abbreviations: AI = autoinjector; PFS-NSD  = pre-filled syringe  with needle safety device.  
4.2. Scientific Rationale for Study Design  
Conducting the study in healthy participants mitigates the potential confounding effects of the 
disease state and concomitant medications in pa rticipants with AD. A population of healthy 
participants is frequently used in the assessment of the PK of both small and large molecules.  
A single dose of lebrikizumab and the PK sampling time points have been selected to generate 
PK profiles sufficient t o fulfill the study objectives.  
Participants will be random ly ass igned to receive injections in the arm, thigh, or abdomen to 
evaluate the impact  injection site has on bioavailability of lebrikizumab.  
Previous population PK analyses have shown that patient s with a lower body weight tended to 
have a lower clearance and volume of distribution  (Zhu  et al.  2017) . While the effects of body 
weight on these PK parameters were statistically significant, it was not considered to be 
clinically relevant. However, to mitigate these potentially confoundin g effects, approximately 
equal numbers of participants in each weight  category are proposed to avoid a large difference in 
mean weight between the test and the reference delivery -device groups. A participant population 
of 72 per weight group is an approximate target with the recommende d weight categories 
selected based on t he distribution of weights in prior studies . The number of participants 
assigned to each delivery device and the number of participants assigned to each site of injection 
is desired to be balanced . 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 19 A parallel -group design is chosen because a crossover desi gn is impractical for lebrikizumab , 
which has a half -life of approximately 25 days. Additionally, a crossover study could confound  
PK data if participant s develop neutralizing ADAs.  
4.3. Justification for Dose  
A 250-mg dose of lebrikizumab has been selected  for this study  for the following reasons:  
• the 250 -mg dose was well  tolera ted in 3 completed Phase 2 studies in patients with AD, 
and  
• the [ADDRESS_1044288] participant in the study.  
Participants may be replaced to ensure that approximately 216 participants (108 in each group) 
complete the study  (see Section 9.2). 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 20 5. Study Population  
Eligibility of participants for enrollment in the study will be based on the results of screening 
medical history, physical examination, vital signs, clinical laboratory tests , and ECG. The nature 
of any conditions present at the time of the physical examination and any preexisting conditions 
will be documented.  
The inclusion and exclusion criteria used to determine eligibility should be applied at screening 
only, and not continuously throughout the trial.  
Screening may occur up to 28 days prior to enrollment. Participants who are not enrolled within  
28 days of scree ning may undergo an additional medical assessment and/or clinical 
measurements to confirm their eligibility. In such instances, repeat the following screening tests 
and procedures:   
• weight  
• vital signs  
• ECG  
• clinical laboratory  tests, and  
• pregnancy test (fema les of childbearing potential  only)  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted.  
5.1. Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following criteria apply:  
Age 
1. Participant must be aged 18 to 65 years inclusive, at the time of signing the informed 
consent.  
Type of participant and disease characteris tics 
2. Participants who ar e overtly healthy as d etermined through  medical evaluation including :  
• medical history  
• physical examinati on (conducted at screening or  Day -1) 
• laboratory tests, and  
• cardiac monitoring . 
3. have clinical laboratory test results within normal reference range for the population or 
investigative site, or results with acceptable deviations that are judged to be not clinically 
significant by [CONTACT_093] . 
Note: Screening and/or Day -1 laboratory testing may be repeated (once) at the discretion 
of the investigator for any out -of-range results.  
4. have venous access sufficient to allow for blood sampling as per the protocol . 
5. agree not to donate blood or plasma until after the end of their participation in the s tudy. 
6. are reliable and willing to make themselves available for the duration of the study and are 
willing to follow study procedures . 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 [ADDRESS_1044289] a body mass index w ithin the range 18.0 to 32.0 kg/m2 (inclusive).  
Sex 
8. are males or nonpregnant females of childbearing or non -childbearing potential.  
• Reproductive definitions and contra ceptive requirements are provided in 
Appendix 4 (Section 10.4) 
Informed  consent  
9. Capable of giving signed informed consent as described in Appendix 1 (Section 10.1), 
which includes compliance with the requirements and restrictions listed in the ICF and in 
this protocol . 
5.2. Exclusion Criteria   
Participants are excluded from the study if any of the following criteria apply:  
Medical conditions  
10. have known allergies to  lebrikizumab , related compounds , or any components of the 
formulation, or history of anaphylaxis as defined by [CONTACT_555766] (Sampson  et al.  
2006)  
11. have an abnormality in the [ADDRESS_1044290] an abnormal blood pressure and/or pulse rate  as determined to be clinically 
significant  by [CONTACT_093] . 
13. have  a history or presence of  cardiovascul ar, respi[INVESTIGATOR_696], hepatic, renal, gastrointestinal, 
endocrine, hematological, or neurological disorders capable of significantly altering the 
absorption, metabolism, or el imination of drugs; of constituting a risk when taking the 
investigational product; or of interfering with the interpretation of dat a. 
14. have a history or presence of  psychiatric disorders  deemed clinically significant by [CONTACT_1275] . 
15. regularly use known drugs of abuse or show positive findings on drug screening  or 
Day -1. 
16. show evidence of human immunodeficiency virus infection and/or positive human 
immunodeficiency virus  antibodies . 
17. show evidence of hepatitis C and/or positive hepatitis C antibody . 
18. show evidence of hepatitis B and/or positive hepatitis B surface antigen  or hepatitis B 
core antibody.  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 22 19. Infections:  
a. have had a serious infection ( such as , pneumonia, cellulitis, sepsis); 
have been hospi[INVESTIGATOR_762335] n 
within 12  weeks prior to Day 1; have had a serious bone or joint 
infection within [ADDRESS_1044291] ever had an infection 
of an artificial joint; or are immunocompromised to an extent that 
participation in the study would pose an unacceptab le risk to the 
participant  as determined by [CONTACT_093]  
b. have or have had an infection typi[INVESTIGATOR_419631]/or that occurs with increased incidence in an immunocompromised 
host (including, but not limited to, Pneumocystis jirovecii  pneumonia, 
histoplasmosis, or coccidioidomycosis) or have a known 
immunodeficiency  
c. have or have had a herpes simplex  infection , herpes zoster infection , or 
any other clinically apparent varicella  zoster virus infection within 
[ADDRESS_1044292] had an y other active or recent infection within 4 weeks of Day 1 
that, in the opi[INVESTIGATOR_871], would pose an unacceptable risk 
to the participant if participating in the study; these participants may be 
rescreened (once) at least 4  weeks after docume nted resolution of 
symptoms.  
20. show evidence of active or latent TB, as documented through medical history, 
examination, and TB testing (positive [not indeterminate] QuantiFERON®-TB Gold test; 
if a repeat test is also indeterminate, the participant will not be eligible); or have had 
household contact [CONTACT_4490] a person with active TB, unless appropriate and documented 
prophylaxis treatment has been given. Participants with any history of active TB are 
excluded from the study, regardless of previous or current TB t reatments . 
21. medical history of allergic reaction  to humanized monoclonal antibodies . 
22. clinically significant multiple or severe drug allergies, intolerance to topi[INVESTIGATOR_030], or severe posttreatment hypersensitivity reactions (including, but not 
limited to, erythema multiforme major, linear immunoglobulin A dermatosis, toxic 
epi[INVESTIGATOR_77116], history of anaphylaxis , and exfoliative dermatitis) . 
23. ALT  or AST >1.5x ULN . 
24. TBL  >1.5x ULN (isolated bilirubin >1.5x ULN is acceptable if TBL  is fractionated and 
direct bilirubin <35%) . 
25. absolute eosinophil count >ULN . 
26. current or chronic history of liver disease. This inc ludes but is not limited to hepatitis 
virus infections, drug - or alcohol -related liver disease, nonalcoholic steatohepatitis, 
autoimmune hepatitis, hemochromatosis, Wilson’s disease, α -1 antitrypsin deficiency, 
primary bil iary cholangitis, primary sclerosing cholangitis, or any other liver disease 
considered clinically significant by [CONTACT_093] . 
27. known hepatic or biliary abnormalities (with the exception of Gilberts syndrome or 
asymptomatic gallstones) . 
28. have donated bl ood of more than 500 mL within the previo us 4 weeks  of study screeni ng. 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 [ADDRESS_1044293] 10 years . 
31. are females who are pregnant or lactating . 
Prior/ concomitant therapy  
32. have participated in a clinical trial involving an investigational product  within 30 days or 
5 half-lives (whichever is longer) prior to screening . If the clinical trial involved 
treatment with biologic agents (such as monoclonal antibodies, including marketed 
drugs), at least 3 months or 5 half -lives (whichever is longer) should have elapsed prior to 
Day [ADDRESS_1044294] previously completed or withd rawn from this study or any other study investigatin g 
lebrikizumab . 
34. intend to use over -the-coun ter or prescription medication  including herbal 
medications  within  7 days prior to dosing.  Specific medications listed in Sectio n 6.5, may 
be allowed . 
35. live vaccine(s) within 12 weeks  prior to screening or plans to receive such vaccines 
during the study . 
36. it is suggested  that participants do not receive nonlive or inactivated vaccinations from 
2 weeks prior to, until 2 weeks after lebrikizumab dosing . 
37. treatment with biologic agents (such as monoclonal antibodies including marketed drugs) 
within 3 months or 5 half -lives (whichever is longer) prior to dosing . 
Prior/ concurrent clinical study experience  
38. are currently  enrolled  in any other  clinical  study  involving  an investigational  product  or 
any other  type of medical  research  judged  not to be scientifically  or medically  compatible  
with this study . 
39. are Lilly  employee s or are empl oyees  of Covance . 
40. are investigator  site personnel  directly  affiliated  with this study  and/or  their immediate  
families.  Immediate  family  is defined  as a spouse,  parent,  child,  or sibling,  whether  
biological  or legally  adopted . 
Other exclusions  
41. have an average weekly alcohol intake exceeding >21 units for males or > 14 units for 
females. One unit is equivalent to 8 g of alcohol: a half pi[INVESTIGATOR_11731] (approximately  240 mL) of 
beer, 1 glass (125 mL) of wine, or 1 (25 mL) measure of spi[INVESTIGATOR_2120].  
42. are unwilling to stop alcohol consumption  [ADDRESS_1044295] excessive tattoos, scars, moles, skin hyperpi[INVESTIGATOR_371], birth marks, or stretch 
marks over either arm, either thigh, or either side of the abdomen that would interfere 
with injection -site assessments . 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 [ADDRESS_1044296] 
meals will be provided at all other times while participants are resident at the CRU, per the 
CRU’s policy.  
5.3.2.  Caffeine, Alcohol, and Tobacco  
Caffeine  
Participants  will not be allowed to consume caffeinated products during study visits and while 
resident at the CRU , but otherwise  participants will be allowed to maintain their regular caffeine 
consumption.  
Alcohol  
Alcohol consumption is not permitted while participants are resident at the CRU and for 
[ADDRESS_1044297] abide by [CONTACT_61514].  
5.3.3.  Activity  
Participants will be advised to maintain their regular levels of physical activity/exercise; 
however, they should not undertake vigorous or prolon ged exercise within 48 hours prior to any 
visit in which laboratory safety tests will occur (Day -1, Day 1, Day 3, Day 15, Day 29 , and Day 
99). While certain study procedures are in progress at the site, participant s may be required to 
remain recumbent or sitting.  
5.4. Screen Failures  
Screen failures are defined as participant s who consent to participate in the clinical study  but are 
not subsequent ly enrolled  in the study . 
Individuals who do not meet the criteria for participation in this study (screen failure ) may be 
rescreened  once , based upon  investigator or designee  discretion and discussion with Lilly clinical 
pharmacologist . Rescreened participants should be assigned a new participant number  and must 
sign a new ICF.  
Repeating of laboratory tests during the screening period or repeating screening tests to comply 
with the protocol -designated screening period , as stated in Section 5, does not constitute 
rescreening.  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 25 6. Study Intervention  
Study intervention is defined as an y investigational intervention (s), marketed product(s), 
placebo , or medical device (s) intended to be administered to /used by  a study participant 
according to the study protocol.  
6.1. Study Interventions Administered  
This study involves a comparison of 2-mL (125 mg/mL) SC injections  of lebrikizumab using 
PFS-NSD  and AI into th e arm, thigh, or abdomen f or a total administered dose of 250 mg (Table  
KGBG .2). 
Table  KGBG .2. Study Interventions Administered  
Study Intervention  Lebrikizumab PFS -NSD  Lebrikizumab  AI 
Dosage Formulation  Solution for injection  Solution for injection  
Unit Dose 
Strength(s)/Dosage Level(s)  125 mg/mL in a 2-mL PFS -NSD   125 mg/mL in a 2-mL AI 
Route of Administration  Subcutaneous  Subcutaneous  
Dosing Instructions  2-mL injections at site according to the 
randomization  2-mL injections at site according to 
the randomization  
Abbreviations: AI = autoinjector; PFS-NSD  = pre -filled syringe  with needle safety  device .  
6.1.1.  Medical  Devices  
• Lebrikizumab will be administered by [CONTACT_1719] , using a PFS -NSD and 
an AI . 
• Instructions on how to use the  PFS-NSD and the AI will be provided . 
• All product compla ints (including malfunction, use error , and inadequate l abeling) shall 
be documented and reported by [CONTACT_31819] (see 
Section  8.3) and appropriately managed by [CONTACT_456].  
• Each device  will be labeled according to the country’s regulatory requirements . 
6.2. Preparation/Handling/Storage/Accountability  
• The investigator or designee must confirm appropriate storage  conditions have been 
maintained during transit for all study intervention s received and any discrepancies are 
reported and resolved before use of the study intervention.  
• Only participants enrolled in the study may receive study intervention . Only study 
personnel  may supply , prepare,  or administer study intervention.  All study intervention s 
must be stored in a secure, environmentally controlled, and monitored (manual or 
automated) area in accordance with the labeled storage conditions with access limited to 
the investigator and authorized  study personnel . 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 26 • The investig ator or authorized study personnel are  responsible for study intervention 
accountability, reconciliation, and record maintenance (i .e., receipt, reconciliation, and 
final disposition records).  
• Further guidance and information for the final disposition of u nused study interventions 
are provided separately . 
6.3. Measures to Minimize Bias: Randomization and Blinding  
This is an open -label study. In order to minimize potential bias, assignment to treatment groups 
will be determined by a computer -generated random sequ ence using an IWRS. On Day 1 
(referred to as Visit 1 in IWRS), the site will process Visit [ADDRESS_1044298] number 
and randomized in a 1:1 ratio for delivery device (either PFS -NSD or AI) and within each 
delivery device group in a 1:1:1 ratio for injection site (arm, thigh, or abdomen) resulting in a 
1:1:1:1:1:1 ratio between 6 possible assignment options. The randomization will be stratified by 
[CONTACT_762341] (less than 70.0 kg, 70.0 to 80.0 kg, and more than 80.0 kg).  
6.4. Study Intervention Compliance  
Participants are dosed at the site . The investigator or designee  will administer  study intervention 
through  SC injection to participants .  The study intervention  (i.e. device and injection location)  
and study participant identification will be confirmed prior to the time of dosing. The date and 
time of the administration will be recorded in the source documents and in the CRF.  
6.5. Concomitant Therapy  
Parti cipants must abstain from taking prescription or nonprescription drugs (including vitamins 
and dietary or herbal supplements) within 7 days (or 14 days if the drug is a potential enzyme 
inducer) or 5 half -lives (whichever is longer) before the start of stu dy intervention until 
completion of the last visit, unless, in the opi[INVESTIGATOR_110409], the medication 
will not interfere with the study.  
Participants on stable concomitant medication at the time of study entry should continue their 
regular, unchanged dose throughout the study. Permitted concomitant medications, at the 
discretion of the investigator, include hormonal contraceptives, hormone -replacement therapy, 
and thyroid replacement. Inclusion of participants on any other concomitant m edication ( for 
example,  statins and anti -hypertensives) is contingent upon approval following consultation with 
the sponso r. 
Acetaminophen , at doses of 3 g/day , is permitted for use  during the study , other th an on the 
dosing day within 4  hours prior to and 4 hours after dosing . Other concomitant medication may 
be considered on a case -by-case basis by [CONTACT_762342] . 
Any medication or vaccine , including over -the-counter or prescription medicines, vitamins, 
and/or herbal supplements that the participant is receiving at the time of enrollment or receives 
during the study must be recorded along with  
● reason  for use  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 27 ● dates  of administration including start and end dates , and  
● dosage  information including dose and frequency  for concomitant therapy of 
special interest . 
The medical monitor  should be contact[CONTACT_63193].  
Participants will be restricted from applying any creams or lotions on the arm, thigh, or 
abdominal skin within 24 hours prior to or after the injections and participants should not receive 
any additional SC injections at the site of lebrikizumab administr ation for the duration of the 
study . 
6.6. Dose Modification  
Not applicable.  
6.7. Intervention  after the End of the Study  
Not applicable.  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 28 7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal  
7.1. Discontinuation of Study Intervention  
Not applicable . 
7.2. Participant Discontinuation/ Withdrawal from the Study  
A participant  may withdraw from the study  
● at any time at his/her own request  
● at the request of his/her designee ( for example , parents or legal guardian)  
● at the discretion of the invest igator for safety, behavioral, compliance, or 
administrative reasons  
● if the participant becomes pregnant during the study , and  
● if enrollment in any other clinical study involving an investigational product or 
enrollment in any other type of medical res earch judged not to be scientifically or 
medically compatible with this study  
At the time of discontinuing from the study, if possible, an early discontinuation visit should be 
conducted, as shown in the S oA.  See SoA for data to be collected at the time of study 
discontinuation and follow -up and for any further evaluations that need to be completed . The 
participant  will be permanently discontinued both from the study intervention s and from the 
study at that time . 
If the participant  withdraws consent  for d isclos ure of future information, the s ponsor may retain 
and continue to use any data collected before such a withdrawal of consent .  If a participant  
withdraws from the study, he/she may request destruction of any samples taken and not tested , 
and the inve stigator must document this in the site study records .  
7.2.1.  Discontinua tion of Inadvertently Enrolled Participants  
If the sponsor or investigator identif ies a participant  who did not meet enrollment criteria and 
was inadvertently enrolled, then the participant  should be discontinued from study treatment 
unless there are extenuating circumstances that make it medically necessary for the participant  to 
continue on study treatment.  If the investigator and the sponsor CRP agree it is medically 
appropriate to continue, the investigator must obtain documented approval from the sponsor CRP 
to allow the inadvertently enrolled participant to continue in the  study with or without treatment 
with investigational product.  Safety follow -up should be performed as outlined in Section 1.3 
(Schedule of Activi ties), Section 8.2 (Safety Assessments) , and Section 8.3 (Adverse Events and 
Serious Adverse Events)  of the protocol.   
7.3. Lost to Follow -up 
A participant will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contact[CONTACT_9298].   Site personnel or designee are 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 [ADDRESS_1044299] participants who fail to return for a scheduled visit 
or were otherwise unable to be followed up by [CONTACT_779].  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 30 8. Study Assessments and Procedures  
Study procedures and their timing are summarized in the SoA  (Section 1.3).  
Immediate  safety concerns  should be discussed with the s ponsor immediately upon occurrence or 
awareness to determine if the participant should continue or discontinue study intervention . 
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for study conduct.  
All screening evaluations must be completed and reviewed to confirm that  potential participant s 
meet all eligibility criteria.  The investigat or will maintain a screening log to record details of all 
participant s screened and to confirm eligibility or record reasons for sc reening failure, as 
applicabl e.  
The specifications in this protocol for the timings of safety and sample collection are give n as 
targets to be achieved within reasonable limits. Modifications may be made to the time points 
based upon emerging clinical information. The scheduled time points may be subject to minor 
alterations; however, the actual time must be correctly recorded in the CRF.   Failure or being late 
(i.e. outside stipulated time allowances) to perform procedures or obtain samples due to 
legitimate clinical issues ( for example,  equipment technical problems, venous access difficulty, 
or participant  defaulting or turning up late on an agreed scheduled procedure) will not be 
considered as protocol deviations but the CRU will still be required to notify the sponsor in 
writing via a file note.  
Appendix  2 (Section 10.2) lists the laboratory tests that will be performed for this study.  
Appendix 2 (Section  10.2.1 ) provides a summary of the maximum number and volume of 
invasive samples, for all sampling, during the study.  
Unless otherwise stated in the following subsections, all samples collected for specified 
laboratory tests will be destroyed within [ADDRESS_1044300] results . Certain 
samples may be retained for a longer period, if necessary, to comply with applicable laws, 
regulations, or laboratory certification standards.  
8.1. Efficacy Assessments  
Efficacy is not evaluated in this study.  
8.2. Safety A ssessments  
Planned time points for all safety assessments are provided in the SoA  (Section 1.3). 
8.2.1.  Physical Examinations  
A complete physical examinati on will include, at a minimum, ass essments of the cardiovascular, 
respi[INVESTIGATOR_696], gastrointestinal , and neurological  systems. Height and w eight will also be measured 
and recorded.   
Investigators should pay special attention to clinical signs related to previous serious illnesses.  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 31 8.2.2.  Vital Signs  
For each  participant , vital s ign measurements should be conducted according to the So A 
(Section  1.3).  
Bloo d pressure and pulse rate should be measured after at le ast [ADDRESS_1044301] 3 minutes.   
If the participant feels unable to stand, supi[INVESTIGATOR_47538].  
Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or 
posture -induced symptoms.   Additional vita l signs may be measured during each study period if 
warranted.   
8.2.3.  Electrocardiograms  
Single  12-lead ECG wil l be obtained as outlined in the SoA (see Section  1.3). 
ECGs must be recorded before collecting any blood samples. Participants must be supi[INVESTIGATOR_51938] [ADDRESS_1044302] ion. E CGs may be obtained at additional times, when deemed clinically necessary. All 
ECGs recorded should be stored at the investigational site.  
ECGs will be interpreted by a qualified investigator (the physician or qualified designee) at the 
site as soon after the time of ECG collection as possible, and ideally while the participant is still 
present, to determine whether the participant meets entry cri teria at the relevant visit(s) and for 
immediate participant management, should any clinically relevant findings be identified.  
Any new clinically relevant finding should be reported as an AE.  
8.2.4.  Clinical Safety Laboratory Assessments  
See Appendix 2 (Section  10.2) for the list of clinical laboratory tests to be performed and to the 
SoA (Section 1.3) for the timing and frequency.  
The investigator must review the laboratory results , document this review, and report  any 
clinically relevant changes occurring during the study as an AE . The laboratory results must be 
retained with source documents unless a Source Documen t Agreement or comparable document 
cites an electronic location that accommodates the expected retention duration. Clinically 
significant abnormal laboratory findings are those that are not associated with the underlying 
disease, unless judged by [CONTACT_19448]'s 
condition.  
All laboratory tests with values considered clinically significantly abnormal during participation 
in the study s hould be repeated until the values return to normal or baseline or are no longer 
considered clinically significant by [CONTACT_10982].  
If such values do not return to normal/baseline within a period of time judged reasonable by [CONTACT_1275], the etiology should be identified and the sponsor notified.  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 32 All protocol -required laboratory assessments, as defined in Appendix 2  (Section 10.2), must be 
conducted in accordance with the SoA , standard collection requiremen ts, and laboratory manual . 
If laboratory values from nonprotocol -specified laboratory assessments performed at an 
investigator -designated local laboratory require a change in participant management or are 
considered clinically significant by [CONTACT_093] ( for example,  SAE or AE or dose 
modification), then  report the information as an AE . 
If a central vendor is used for the study, Lilly or its designee will provide the in vestigator with 
the results of laboratory tests analyzed by a central vendor.  
[IP_ADDRESS].  Tuberculosis Testing  
Participants  will be tested as indicated in the SoA (Section 1.3) for evidence of active or latent 
TB using the QuantiFERON -TB Gold test . If the test is indeterminate, [ADDRESS_1044303]  or CRP/scientist  will monitor  safety  data throughout  the course  
of the study . 
Lilly will review SAEs within time frames mandated by [CONTACT_10984].   The Lilly clinical 
pharm acologist or CRP will periodically review   
• trends in safety data   
• laboratory analytes, and    
• AEs.  
When appropriate, the Lilly clinical pharmacologist or CRP will consult with the functionally 
independent Global Patient Safety therapeutic area physician or  clinical research scientist.  
[IP_ADDRESS].  Hepatic Safety  
Close hepatic monitoring  
Laboratory  tests Appendix 6 (Section  10.6), including ALT, AST, ALP, TBL, direct bilirubin , 
gamma -glutamyl transferase , and creatine kinase , should be repeated within 48  to 72 hours  to 
confirm the abnormality and to determine if it is increasing or decreasing , if 1 or more  of these 
conditions occur:  
If a participant with baseline 
results of ...  develops the following elevations:  
ALT or AST <1.5x ULN  ALT or AST ≥3x ULN  
ALP <1.5x ULN  ALP ≥2x ULN  
TBL <1.5x ULN  TBL ≥2x ULN (except for patients with 
Gilbert’s syndrome)  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 [ADDRESS_1044304] ≥1.5x ULN  ALT or AST ≥2x baseline  
ALP ≥1.5x ULN  ALP ≥2x baseline  
TBL ≥1.5x ULN  TBL ≥1.5x baseline (except for patients with 
Gilbert’s syndrome)  
 
If the abnormality persists or worsens, clinical and laboratory monitoring, and evaluation for 
possible causes of abnormal liver test  result s should be initiated by [CONTACT_51994] -designated medical monitor.  At a minimum, this evaluation should 
include physical examination and a thorough medical history, including symptoms, recent 
illnesses (for example, heart failure, systemic infection, hypotension, or seizures), recent travel, 
history of concomitant medications (including over  the counter), herbal and dietary supplements, 
history of alcohol drinking , and other substance abuse.  
Initially, m onitoring of symptoms and hepatic biochemical te sts should be done at a frequency of 
1 to 3 times weekly, based on the participant’s clinical condition  and hepatic biochemical tests. 
Subsequently, the frequency of monitoring may be lowered to once every 1 to 2 weeks, if the 
participant’s clinical condit ion and lab oratory  results stabilize.  Monitoring of ALT, AST, ALP , 
and TBL should continue until levels normalize or return to approximate baseline levels . 
Comprehensive hepatic evaluation  
A comprehensive evaluation should be performed to search for possible causes of liver injury if 
1 or more of these conditions occur:  
If a participant with baseline 
results of...  develops the following elevations:  
ALT or AST <1.5x ULN  ALT or AST ≥3x ULN with hepatic signs/symptoms*, or  
ALT or AST ≥5x ULN  
ALP <1.5x ULN  ALP ≥3x ULN  
TBL <1.5x ULN  TBL ≥2x ULN (except for patients with Gilbert’s syndrome)  
  
ALT or AST ≥1.5x ULN  ALT or AST ≥2x baseline with hepatic signs/symptoms*, or 
ALT or AST ≥3x baseline  
ALP ≥1.5x ULN  ALP ≥2x baseline  
TBL ≥1.5x ULN  TBL ≥2x baseline (except for patients with Gilbert’s 
syndrome)  
* Hepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, rash, 
and/or eosinophilia >5%.  
At a minimum, this evaluation should include physical examination and a thorough medical 
history , as outlined above, as well as  tests for prothrombin time -international normalization ratio ; 
tests for viral hepatitis A, B, C, or E; tests for autoimmune hepatitis; and an abdominal imaging 
study (for example, ultrasound or computed tomography  scan).  
Based on the patient’s history and initial results, further testing should be considered in 
consultat ion with the Lilly -designated medical monitor, including tests for hepatitis D virus , 
cytomegalovirus , Epstein -Barr virus , acetaminophen levels, acetaminophen protein adducts, 
urine toxicology screen , Wilson’s disease, blood alcohol levels, u rinary ethyl  glucuronide,  and 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 34 blood  phosphatidylethanol . Based on the circumstances and the investigator’s assessment of the 
participant’s clinical condition, the investigator should consider referring the participant for a 
hepatologist or gastroenterologist consultatio n, magnetic resonance cholangiopancreatography , 
endoscopic retrograde cholangiopancreatography , cardiac echocardiogram, or a liver biopsy.  
Additional hepatic data collection (hepatic safety CRF) in study participants who have abnormal 
liver test  result s during the study  
Additional hepatic safety data collection in hepatic safety CRF s should be performed in study 
participants who meet 1 or more of the following 5 conditions:  
1. Elevation of serum ALT level to ≥[ADDRESS_1044305] on 2 or more consecutive blood tests (if 
baseline ALT <1.5x ULN)  
• In participants with baseline ALT ≥1.5x ULN, the threshold is ALT ≥3x baseline 
on 2 or more consecutive tests  
2. Elevat ion of  TBL level to ≥[ADDRESS_1044306] (if baseline TBL <1.5x ULN) (except for cases of 
known Gilbert’s syndrome)  
• In participants  with baseline TBL ≥1.5x ULN, the threshold should be TBL ≥2x 
baseline  
3. Elevation of serum ALP to ≥[ADDRESS_1044307] on 2 or more consecutive blood tests (if baseline 
ALP <1.5x ULN)  
• In participants with baseline ALP ≥1.5x ULN, the threshold is ALP ≥2x baseline 
on 2 or  more consecutive blood tests  
4. Hepatic event considered to be a n SAE  
5. Discontinuation of study drug due to a hepatic event  
Note: the interval between the [ADDRESS_1044308] 2 days.  
[IP_ADDRESS].  Injection -Site Reactions  
Symptoms of a local ISR may include erythema, induration, pain, pruritus, and edema.  
If an ISR is reported by a participant , investigator , or site staff  as an AE of a local ISR , the ISR 
AE CRF will be used to capture additional information about this reaction (for example, 
injection -site pain, degree and area of erythema, induration, prurit us, and edema).   
In addition, a ll positive responses of injection -site pain will require an additional  assessment 
using the Pain Visual Analog Scale (Williamson and Hoggart 2005).  
[IP_ADDRESS].  Hypersensitivity Reactions  
Many drugs, but particularly biologic agents, carry the risk of systemic hypersensitivity 
reactions. If such a reaction occurs, additional data describing each symptom should be provided 
to the sponsor in the  electronic CRF.  
Sites should have appropriate ly trained medical staff and appropriate medical equipment 
available wh ile study participants are receiving study drug. It is recommended that participants 
who experience a systemic hypersensitivity reaction be treated per national and international 
guidel ines. 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 35 In the case of generalized urticaria or anaphylaxis, additional blood and urine samples should be 
collected as described in Appendix 7 (Section 10.7). Laboratory results are provided to the 
sponsor via the central laboratory . 
8.3. Adverse Events , Serious Adverse Events , and Product Complaints  
Investigators are responsible for monitoring the safety of participants who have entered this 
study and for alerting Lilly or its designee to any event that seems unusual, even if this event 
may be considered an unanticipated benefit to the participant.   
The investigator is responsible for the appropriate medical care of participants during the study .  
The defin itions of the following events can be found in Appendix 3:  
• AEs 
• SAEs  
• ADEs  
• UADEs  
• SADEs , and  
• product complaints  
These events will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, surrogate, 
or the participant ’s legally authorized representative).  
The investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the se definition s and remain responsible for following up events that 
are serious, considered related to the study intervention or study procedures, or that caused the 
participant to discontinue the study (see Section 7). 
Care will be taken not to introduce bias wh ile detecting events . Open -ended and nonleading 
verbal questioning of the participant is the preferred method to inquire about event occurrences.  
After the initial report, the investigator is required to proactively follow up each participant at 
subsequent visits/contacts. All SAEs will be followed up until resolution, stabilization, the event 
is otherwise explained, or the participant is lost to fo llow-up (as defined in Section 7.3). For 
product complaints, t he investigator is responsible for ensuring that follow -up includes any 
supplemental i nvestigations as indicated to elucidate the nature and/or causality.  Further 
information on follow -up procedures is provided in Appendix 10.3.  
8.3.1.  Timing and Mechanism for Collecting Events  
This table describes the timing, deadlines , and mechanism for collecting events.  
Event  Collection Start  Collection Stop  Timing  for 
Reporting to 
Sponsor or Designee  Mechanism for 
Reporting  
AE Signing of the 
ICF Participation in 
study has ended  As soon as possible 
upon site awareness  AE eCRF  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 36 Event  Collection Start  Collection Stop  Timing  for 
Reporting to 
Sponsor or Designee  Mechanism for 
Reporting  
SAE and SAE updates – 
prior to start of study 
intervention and deemed 
reasonably possibly related 
with study procedures  Signing of the 
ICF Start of 
intervention  Within 24 hours  of 
awareness  SAE eCRF  
SAE  and SAE updates  – 
after start of study 
intervention  Start of 
intervention  Participation in 
study has ended  Within 24 hours of 
awareness  SAE eCRF  
SAE  – after participant’s 
study participation has 
ended and the investigator 
becomes aware  After participant’s 
study 
participation has 
ended  NA Promptly  SAE paper form  
Pregnancy in female 
participants and female 
partners of male 
participants  After the start of 
study intervention  [ADDRESS_1044309] complaint 
information  — — As soon as possible 
upon site awareness  Originally 
completed 
product complaint  
form with all 
changes signed 
and dated by [CONTACT_762343]  (if 
investigator becomes 
aware)  Participation in 
study has ended  NA Promptly  Product complaint  
form  
8.3.2.  Adverse Events of Special Interest  
Adverse events of special interest for this study include  
Approved on 17 Aug 2021 GMT
C O N FI D E N TI A L  J 2 T -M C -K G B G (b) 
 3 7  • c o nj u ncti vitis  
• her pes i nfecti o n or z oster, a n d  
• parasitic i nfecti o n or a n i nfecti o n rel ate d t o a n i ntracell ular p at h o ge n . 
If t hese a d v erse e ve nts of s pecial i nterest  are re p orte d, sites will be pr o m pte d t o c ollect a d diti o nal 
data . 
8. 4.  Tre at me nt of O ver d ose  
F or t his st u d y, a n y d ose of le bri kiz u ma b  greater t ha n 2 5 0 m g  will be c o nsi dere d a n o v er d ose.  
T he sp o ns or d oes n ot rec o m me n d s pecific treat me nt f or a n o ver d ose . 
I n t he e ve nt of a n o ver d ose, t he i n vesti gat or /treati n g p h ysicia n  s h o ul d  
1.  c o ntact  t he me dical m o nit or  i m me diatel y.  
2.  cl osel y  m o nit or t he p artici pa nt f or a n y A E/ S A E a n d la b orat or y a b n or malities . 
8. 5.  P h ar m ac o ki netics  
Bl o o d  sa m ples of a p pr o xi matel y [ADDRESS_1044310] u d y b ase d o n ne wl y a vaila ble d ata ( f or e x a m ple , t o 
o btai n data cl oser t o t he ti me of pea k ser u m  c o nce ntrati o ns) t o e ns ure a p pr o priate m o nit ori n g.  
I nstr u cti o ns f or t he c ollecti o n a n d ha n dli n g of bi ol o gical sa m ples will be pr o vi de d b y t he 
s p o ns or. T he act u al date a n d ti me ( 2 4 -h o ur cl o c k ti me) of eac h sa m ple will be rec or de d.  
8. 5. 1.  Bi o a n al ysis  
Sa m ples will be a nal yze d at a la b orat or y a p pr o ve d b y t he s p o ns or a n d st ore d at a facilit y 
desi g nat e d b y t he s p o ns or .  
Ser u m c o nce ntr ati o ns of  le bri kiz u ma b will be assa ye d  
.  A nal ys es of sa m pl es c ollecte d fr o m place b o -treate d p artici pa nts 
are n ot pla n ne d.   
Bi oa nal ytical s a m ples c ollecte d t o meas ure i n vesti gati o nal pr o d u ct c o nce ntr ati o ns will be 
retai ne d f or a ma xi m u m of [ADDRESS_1044311] u d y.  
A p pr o ve d o n 1 7 A u g 2 0 2 1 G M T C CI 
C CI 
CONFIDENTIAL  J2T-MC-KGBG (b) 
 [ADDRESS_1044312] lebrikizumab . Antibodies may be further characterized and/or 
evaluated for their ability  to neutralize the activity of lebrikizumab .  To interpret the results of 
immunogenicity,  a venous blood  sample will be collected  at the same time points  to determine 
the serum  concentrations of  lebrikizumab .  All samples  for immunogenicity should be 
taken  predose  when applicable and  possible.  
Immun ogenicity will be assessed by a validated assay designed to detect ADAs in the presence 
of lebrikizumab at a laboratory approved by [CONTACT_456]. Samples may be stored for a maximum 
of 15 years (or according to local regulations ) following the last participant’s last visit for the 
study at a facility selected by [CONTACT_456] .  Samples may also be used for development and 
control of an immunogenicity ass ay. 
8.10. Health Economic s 
This section is not applicable for this study.  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 39 9. Statistical Considerations  
9.1. Stati stical Hypotheses  
The primary objective of this study is to evaluate PK following administration of lebrikizumab 
using a PFS-NSD  and an AI. 
9.2. Sample Size Determination  
Approximately 240 participants  may be enrolled so that approximately 216 participants  (108 in 
the lebrikizumab PFS-NSD  [reference] group and 108 in the AI [test] group) complete the study.  
A sample size of 108 participants  per device group will provide a pproximately 90% power that  
the 90% CI of the geometric mean ratio of maximum observed drug  concentration (C max) and 
area under the concentration versus time curve (AUC) between groups  will fall within 
equivalence range of 0.[ADDRESS_1044313] log -normal distribution, the percent coefficients of  variation (%CV) of 
Cmax and AUC are less or equal to 30%, the expected  ratio of geometric means is between 0. 9 
and 1.1, and the %CV are the same for participants  from  each device group.  The 30% CV 
assumption is based on lebrikizumab PK data in several previous studies.  
To properly evaluate AUC  from time zero to infinity  (AUC [0-∞]), lebrik izumab concentrations 
must be collected through at least Day 71. To ensure that approximately 216  participants (108 in 
each group) provide evaluable PK data, approximately 240 participants will be enrolled and 
receive study drug, assuming up to 10% of the participants may not complete through at least 
Day 71. Participants who do not complete at least through Day 22 (a period sufficient to 
determine C max) may be replaced.  The replacement participants should be in the same weight 
category as the original part icipants.  
9.3. Populations for Analyses  
The following populations are defined:  
Population  Description  
Safety   All participants randomly assigned to study intervention and who 
receive  study intervention . Participants will be analyzed 
according to the intervention they actually received . 
Pharmacokinetic Analysis  All enrolled participants who received a full dose of study 
intervention  and have evaluable PK sample.  
9.4. Statistical Analyses  
Statistical analysis of this study will be the responsibility of  the sponsor  or its designee . 
9.4.1.  General Considerations  
PK analyses will be conducted on data from all participants  who receive the complete single 
dose of lebrikizumab  and have sufficient evaluable PK data .  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 [ADDRESS_1044314] 
time point with a measurable concentration  (AUC[[ADDRESS_1044315]]), AUC(0 -∞), and C max of 
lebrikizumab . The time of C max (tmax) will also be reported. Other  noncompartmental 
parameters, such as slope of terminal elimination phase, half-life ( t1/2), apparent oral  clearance, 
and apparent volume of distribution during  the terminal elimination phase may be  reported as 
appropriate.  
The primary PK parameter estimates for lebrikizumab  will be compared between the reference 
PFS-NSD  (R) and test AI (T). Log -transformed C max, AUC([ADDRESS_1044316]), and AUC(0 -∞) estimates 
will be  evalu ated in a linear mixed -effects model with fixed effects for weight group, 
injection -site location , and device  group , and a random effect for participant . The treatment 
differences  will be back  transformed to present the ratios of geometric means and the 
corresponding 90%  CIs. Comparisons will be made between the 2 devices .  
Bioequivalence between the PFS-NSD  and the AI will be declared if the 90% CI for AUC(0 -∞), 
AUC([ADDRESS_1044317]), and C max are contained within the 0.[ADDRESS_1044318]. A 
Hodges -Lehmann estimate of the median differences, 90% CIs,  and p -values will be calculated 
for both treatments .  
PK parameter estimates will be summarized b y weight category (<70 kg, 70  to 80 kg, and 
>80 kg) as well as injection -site location (abdomen, arm , thigh) for each device group as 
appropriate. Additional analyses may be conducted if deemed appropriate.  
9.4.3.  Safety Analyse s 
All safety analyses will be made on the Safety Population.  All AEs will be listed, and if the 
frequency of events allows, safety  data will be summarized using descriptive methodology.  The 
incidence of AEs for each  device  will be presented by [CONTACT_762344]. AEs reported to occur prior to study entry will be  
distinguished from those reported as new or increased in severity during the study. Each  AE will 
be classified by [CONTACT_762345] . The 
number of SAEs will be reported.  
9.4.4.  Evaluation of Immunogenicity   
The frequency and percentage of participants  with preexisting ADAs and with TE -ADAs to 
lebriki zumab will be tabulated. T E-ADAs are defined as those with a titer 2 -fold (1 dilution) 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 41 greater than the minimum required dilution if no ADAs were detected at baseline  (treatment -
induced ADA) or those with a 4 -fold (2 dilutions) increase in titer compared to  baseline if ADAs 
were dete cted at baseline (treatment -boosted ADA). For the TE -ADA  subjects, the distribution 
of maximum titers will be described. The frequency of neutralizing  antibodies will also be 
tabulated in TE -ADA subjects.  The relationship between the presence of antibodies  and the 
safety and PK parameters to  lebrikizumab may be assessed.  
9.5. Interim Analyses  
No interim analyses are planned for this study.  If an unplanned interim analysis is deemed 
necessary  the Lilly clinical pharmacologist, investigator, or designee will consult with  the 
appropriate medical director or designee to determine if it is necessary to amend the protocol.  
9.6. Data Monitoring Committee (DMC)  
No data monitoring committee is required for this study.  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 42 10. Supporting Documentation and Operational Consideration s 
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  
10.1.1.  Regulatory and Ethical Considerations  
This study will be conducted in accordance with the protocol and with the following:  
• Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences International Ethical Guidelines  
• Applicable ICH GCP Guidelines  
• Applicable laws and regulations  
The protocol, protocol amendments, ICF, Investig ator’s Brochure, and other relevant documents 
(for example , advertisements) must be submitted to an IRB/IEC by [CONTACT_97277]/IEC  before the study is initiated.  
Any amendments to the protocol will require IRB/IEC appr oval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants.  
The investigator will be responsible for the following:  
• Providing written summaries of the status of the st udy to the IRB/IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established by 
[CONTACT_1201]/IEC  
• Notifying the IRB/IEC of SAEs  or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures  
• Providing oversight  of study conduct for participants under their responsibility and 
adherence to requirements of 21 C ode of Federal Regulations , ICH guidelines, the 
IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local re gulations  
Investigator sites are compensated for participation in the study  as detailed in the clinical trial 
agreement . 
10.1.2.  Informed Consent Process  
The investigator or his/her representative will explain the nature of the study , including the risks 
and benef its, to the participant or his/her legally authorized representative  and answer all  
questions regarding the study.  
Participants must be informed that their participation is voluntary. Participants or their legally 
authorized representative will be required  to sign a statement of informed consent that meets the 
requirements of [ADDRESS_1044319] requirements, where applicable, and the I RB/IEC 
or study cente r. 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 [ADDRESS_1044320] current version of the ICF(s) during th eir 
participation in the study.  
A copy of the ICF(s) must be provided to the participant or the participant’s legally authorized 
representati ve and is kept on file . 
10.1.3.  Data Protection  
Participants will be assigned a unique identifier by [CONTACT_456]. Any participant records , datasets , 
or tissue samples  that are transferred to the sponsor will contain the identifier only; participant 
names or any information that would make the participant identi fiable will not be transferred.  
The participant must be informed that his/her personal study -related data will be used by [CONTACT_20004]. The level of disclosure must also b e 
explained to  the participant  who will be required to give consent for his/her data to be used as 
described in the informed consent .  
The participant must be informed that his/her medical records may be examined by [CONTACT_762346] d personnel appointed by [CONTACT_456], by 
[CONTACT_6667]/IEC members, and by [CONTACT_6668].  
The sponsor has processes in place to ensure data protection, information security , and data 
integrity.  These processes include appropriat e contingency plan(s) for appropriate and timely 
response in the event of a data security breach.  
10.1.4.  Dissemination of Clinical Study Data  
Communication of suspended or terminated dosing  
If a decision is taken to suspend or terminate dosing in the trial due to  safety findings, this 
decision will be communicated by [CONTACT_17083] (for example, through phone and/or 
email) as soon as possible. It will be a requirement that investigators respond upon receipt to 
confirm that they understand the communica tion and have taken the appropriate action prior to 
further dosing any participants with study intervention. Any investigator not responding will be 
followed up by [CONTACT_762347]. If a dose is planned 
imminently, Lilly personnel will immediately, and continually, use all efforts to reach 
investigators until contact [CONTACT_762348].  
Reports  
The sponsor will disclose a summary of study information, including tabular study results, on 
publicly availabl e websites where required by [CONTACT_51967].  
Data  
The sponsor does not proactively share data from Phase 1 clinical trials.   Requests for access to 
Phase 1 clinical trial data are evaluated on a case -by-case basis taking into consideration the 
ability to anonymize the data and the nature of the data collected.  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 44 10.1.5.  Data Quality Assurance  
Investigator responsibilities   
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee  electronically ( for example , laboratory data). The 
investigator is responsible for verifying that data entries are accurate and correct by [CONTACT_18027].  
The investigator must maintain accurate documentation (source data) th at supports the 
information entered in  the CRF.  
The investigator must permit study -related monitoring, audits, IRB/IEC review, and regulatory 
agency inspections and provide direct a ccess to source data documents.  
Data management and monitoring  
Monitoring d etails describing strategy ( for example , risk -based initiatives in operations and 
quality such as risk management and mitigation strategies and analytical risk -based monitori ng), 
methods, responsibilities , and requirements, including handling of noncomplia nce issues and 
monitoring techniques are provided in the Monitoring Plan . 
The sponsor or designee is responsible for the data management of this study includin g quality 
checking of the data.  
The sponsor assumes accountability for actions delegated to other  individuals ( for example , 
contract research organizations ). 
Study monitors will perform ongoing source data verification to confirm that data entered into 
the CRF by [CONTACT_1191], complete, and verifiable from source 
documents; t hat the safety and rights of participants are being protected; and that the study is 
being conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP, and all applicable regu latory requirements.  
Records retention and audits  
Records and documents, including signed ICFs, pertaining to the conduct of this study must be 
retained by [CONTACT_730015] a longer retention period. No records may be 
destroyed during the retention period without the written approval of the sponsor. No records 
may be transferred to another location or party without w ritten notification to the sponsor . 
In addition, the sponsor  or its representatives will periodically check a sample of the participant  
data recorded against source documents at the study site. The study may be audited by [CONTACT_11001] , and/or regulatory agencies at any time. Investigators will be given 
notice before an audit occurs.  
Data capture system  
The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness 
of the data reported to the sponsor . 
An electronic data capture system will be used in this study for the collection of CRF data.  The 
investigator maintains a separate source for the data entered by [CONTACT_762349] 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 45 the sponsor -provided electronic data capture  system.  The investigator is responsible for the 
identification of any data to be considered source and for the confirmation that data reported are 
accurate and complete by [CONTACT_11003] . 
Data collected via the sponsor -provided  data capture system (s) will be  stored at third  party. The 
investigator will have continuous access to the data during the study and until decommissioning 
of the data capture system (s).  Prior to decommissioning, the investigator will receive an archival 
copy of pertinent data for retention.  
Data managed by a central vendor, such as laboratory test data, will be stored electronically in 
the central vendor’s database system and reports  will be  provided to the investigator for review 
and retention.  Data will subsequently be transferred from the  central vendor to the sponsor  data 
warehouse.  
Data from complaint forms submitted to the sponsor  will be encoded and stored in the global 
product complaint management system.  
10.1.6.  Source Documents  
Source documents provide evidence for the existence of the part icipant and substantiate the 
integrity of the data collected. Source documents are filed at the investigator’s site.  
Data reported on the CRF or entered in the e lectronic CRF that are transcribed from source 
documents must be consistent with the source doc uments or the discrepancies must be explained. 
The investigator may need to request previous medical records or transfer records, depending on 
the study. Also, current medical records must be available.  
Definition of what constitutes source data can be fou nd in  Section 10.1.[ADDRESS_1044321] been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in  advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_11004]  
• failure of the investigator to comply with the protocol, the requirements of the IRB/IEC 
or local health a uthorities, the sponsor ’s procedures, or GCP guidelines  
• inadequate recruitment of participants by [CONTACT_093]  
• discontinuation of further study intervention development . 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 46 If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) 
used in the study of the reason for termination or suspension, as  specified by [CONTACT_11005]. The investigator shall promptly inform the participant  and assure s 
appropriate participant  therapy and/or follow -up. 
10.1.8.  Publication Policy  
In accordance with the sponsor’s publication policy, the results o f this study will be submitted 
for publication by a peer -reviewed journal if the results are deemed to be of significant medical 
importance.  
  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 47 10.2. Appendix 2: Clinical Laboratory Tests  
The tests detailed below will be perfor med by [CONTACT_762350] , as 
detailed in the following  table . 
In circumstances where the sponsor approves local laboratory testing in lieu of central laboratory 
testing (in the following  table), the local  laboratory must be qualified in accordance with 
applicable local regulations.  
Protocol -specific requirements for inclusion or exclusion of participants are detailed in Section [ADDRESS_1044322] document their review of the laboratory safety results . 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 48 Safety Laboratory Tests   
Clinical Laboratory Tests  Comments  
Hematology  Performed locally at Screening and Day -1 and 
centrally at Day 1 predose and all postdose time  
points unless  otherwise stated.   
Hematocrit   
Hemoglobin   
Erythrocyte count (RBC)   
Mean cell volume   
Mean cell hemoglobin   
Mean cell hemoglobin concentration   
Leukocytes (WBC)   
Platelets   
Cell morphology (RBC and WBC)   
Differential counts (% and absolute) of:   
Neutrophils   
Lymphocytes   
Monocytes   
Eosinophils   
Basophils   
  
Urinalysis  Performed locally at Screening and Day -1 and 
centrally at Day 1 predose unless otherwise stated.  
Specific gravity   
pH  
Protein   
Glucose   
Ketones   
Bilirubin   
Urobilinogen   
Blood   
Nitrite   
Microscopic examination of sediment   
  
Clinical Chemistry  Performed locally at Screening and Day -1 and 
centrally at Day 1 predose and all postdose time  
points unless otherwise stated.  
Sodium   
Potassium   
Bicarbonate   
Chloride   
Calcium   
Phosphorus   
Glucose   
Blood urea nitrogen (BUN)   
Creatinine   
Uric acid   
Total cholesterol   
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 [ADDRESS_1044323] bilirubin   
Alkaline phosphatase (ALP)   
Aspartate aminotransferase (AST)   
Alanine aminotransferase (ALT)   
Gamma -glutamyl transferase (GGT)   
  
Other tests   
Ethanol testing   Tests may be repeated locally at additional time 
points at the discretion of the investigator  
Urine drug screen  Tests may be repeated locally at additional time 
points at the discretion of the investigator  
Hepatitis B surface antigen  Performed at screening only  
Hepatitis B core antibody  Performed at screening only  
Hepatitis B surface antibody  Performed at screening only  
Hepatitis C antibody  Performed at screening only  
HIV Performed at screening only  
QuantiFERON ®-TB Gold  Performed at screening only  
Pregnancy test (females of ch ildbearing potential  only)   
 Performed at screening , Day -1, and Day 99 or 
early discontinuation.  
FSH (females only)   Performed  at screening only  
Abbreviations: FSH = follicle -stimulating hormone; HIV = human immunodeficiency virus; RBC = red blood cell; 
WBC = white blood cell.  
10.2.1.  Blood Sampling Summary  
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sampling (screening, safety laboratories, and bioanalytical assays) during the  study .  
Protocol J2T-MC-KGBG  Sampling Summary  
 
Purpose  Approximate Blood 
Volume per Sample (mL)   Number of Blood 
Samples  Total Volume 
(mL)  
Screening tests a 45 1 45 
Local c linical laboratory and 
pregnancy testsa 12 2 24 
Central clinical laboratory tests a 4.5 5 22.5 
Pharmacokinetics  3 13 39 
Immunogenicity  10 4 40 
Pharmacogenetics  10 1 10 
Total    180.5 
Total for clinical purposes  190 
a Additional samples may  be drawn if needed for safety purposes.  
  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 50 10.3. Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  
• The definitions and procedures detailed in this appendix are in accordance with 
International Organization  for Standardization [ZIP_CODE].  
• Both the investigator and the sponsor will comply with all local medical device reporting 
requirements.  
• The detection and documentation procedures described in this protocol apply to all 
sponsor medical devices provided for use in the study. See Section 6.1.[ADDRESS_1044324] of 
sponsor medical devices.  
10.3.1.  Definition of AE s and ADE  
AE and ADE  Definition s 
• An AE is  any untoward medical occurrence in a participant administered a 
pharmaceutical product and  which does not necessarily have a causal relationship with 
the study intervention. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory finding), symptom, or disease  (new or exacerbated)  
temporally associated with t he use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product . 
• An ADE is a nonserious AE that can be attributed to a device .  Any untoward medical 
occurrence, unintended disease or injury, or untoward cl inical signs (including 
abnormal laboratory finding) in study participants, users, or other persons, whether or 
not related to the investigational medical device. This definition includes events related 
to the investigational medical device or comparator a nd events related to the 
procedures involved except for events in users or other persons, which include only 
events related to investigational devices.   
 
Events Meeting  the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments ( for ex ample , ECG, radiological scans, vital sign 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator ( that is , not related 
to progression of underlying disease).  
• Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after study interv ention administration even 
though they may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as an 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 51 AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdose should be reported regardless of sequelae.  
 
Events NOT  Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments that are associated with the underlying disease, unless judged by [CONTACT_11009]’ s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition.  
• Medical or surgical procedure ( for example , endoscopy, appe ndectomy): the condition 
that leads to the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).  
• Anticipated day -to-day fluctuations of preexisting disease(s) or condition (s) present or 
detected at the start of the study that do not worsen.  
10.3.2.  Definition of SAE , SADE , and UADE  
If an event is not an AE per the definition above, then it cannot be an SAE even if serious 
conditions are met ( for example , hospi[INVESTIGATOR_1080]/symptoms of the disease under study, 
death due to progression of disease).  
SAE is defined as any untoward medical occurrence that, at any dose:  
a. Results in death  
b. Is life  threatening  
The term “life-threatening ” in the definition of “serious ” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, which 
hypothetically might have caused death, if it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_10909]  
• In general, hospi[INVESTIGATOR_762336]/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Complications that occur during  hospi[INVESTIGATOR_10911]. If a complication prolongs hospi[INVESTIGATOR_9236], 
the event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was 
necessary, the AE should be considered serious.  
• Hospi[INVESTIGATOR_63336] a preexisting condition that did not worsen 
from baseline is not considered an AE.  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 52 d. Results in persistent disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct 
normal life funct ions.  
• This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma ( for example , sprained ankle) , which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
• Abnormal pregnancy outcomes ( for example , spontaneous abortion, fetal death, 
stillbirth, congenital anomalies, ectopic pregnancy) are consid ered SAEs.  
f. Other situations:  
• Medical or scientific judgment should be exercised in deciding whether SAE reporting 
is appropriate in other situations such as important medical events that may not be 
immediately life  threatening or result in death or hospi[INVESTIGATOR_557412] 1 of the other 
outcomes listed in the above definition. These events should usually be considered 
serious.  
• Examp les of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias , or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency or 
drug abuse .  
SADE definition  
A SADE is defined as an adverse device effect that has resulted in any of the consequences 
characteristic of an SAE.  
UADE  definition  
A UADE is a SADE which by [CONTACT_5942], incidence, severity , or outcome has not been 
identified in the current version of the risk analysis report.  
10.3.3.  Recording and Follow -Up of AE and/or SAE  
AE and SAE  
• When an AE/SAE  occurs, it is the responsibility of the investigator to review all 
documentation ( for example , hospi[INVESTIGATOR_1088], laboratory reports, and 
diagnostics reports) related to the event.  
• The investigator will then record all relevant AE/ SAE  information in the participant’s 
medical records, in accordance with the investigator’s normal clinical practi ce. 
AE/SAE information is reported o n the appro priate electronic CRF page . 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 53 • It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to the sponsor or designee  in lieu of completion of the AE/SAE electronic  CRF  
page . 
• There may be instances when copi[INVESTIGATOR_61499] . In this case, all participant identifiers, with the exception of 
the participant number, will be redacted on the copi[INVESTIGATOR_762337] . 
• The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be d ocumented as the AE/SAE . 
Assessment of Intensity  
The investigator will make an assessment of intensity for each AE and SAE reported during 
the study and assign it to 1 of the following categories:   
• Mild:  A type of AE that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual activities of 
daily living . 
• Moderate:  A type of AE that is usually alleviated with additional specific therapeu tic 
intervention. The event interferes with usual activities of daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research 
participant . 
• Severe: A type of AE that interrupts usual activities of daily living, or signi ficantly 
affects clinical status, or may require intensive therapeutic intervention . An AE that is 
assessed as severe should not be confused with a n SAE. Severe is a category utilized 
for rating the intensity of an event; and both AEs and SAEs can be asses sed as severe.  
An event is defined as “serious ” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.  
 
Assessment of Causality  
• The investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE.  
• A “reasonable possibility ” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be 
ruled o ut. 
• The investigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention 
administration will be considered and investigated.  
• The investigator will also con sult the Investigator’s Brochure in hi s/her assessment.  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 54 • For each AE/SAE, the investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provi ded an assessment of causality.  
• There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor or designee . 
However, it is very important that the investigator always make an assessment of 
causality for every event before the initial transmission of the SAE data to the sponsor 
or designee . 
• The investigator may change his/her opi[INVESTIGATOR_762338]-up 
information and send a SAE follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
 
Follow -up of AEs and SAEs  
• The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_730017]/or causality of the AE or SAE as fully as 
possible. This may include additional laboratory tests or investigations, 
histopathological examinations, or consultation with other health care professionals.  
• If a participant dies during participation in the study or during a recognized follow -up 
period,  the investigator will provide the sponsor or designee  with a copy of any 
postmortem findi ngs including histopathology.  
10.3.4.  Reporting of SAEs  
SAE Reporting via SAE Report  
• Facsimile transmission of the SAE paper CRF is the preferred method to transmit this 
information to the sponsor or designee . 
• Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the  designated reporting time frames.  
• Contacts for SAE reporting can be found in the SAE report . 
10.3.5.  Regulatory Reporting Requirements  
SAE Regulatory Reporting  
Prompt notification by [CONTACT_11012] a n SAE is essential so that legal 
obligations and ethical responsibilities toward the safety of participants and the safety of a 
study intervention under clinical investigation are met.  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 55 ● The sponsor has a legal responsibility to notify both the local regula tory 
authority and other regulatory agencies about the safety of a study intervention 
under clinical investigation. The sponsor will comply with country -specific 
regulatory requirements relating to safety reporting to the regulatory authority, 
IRBs/IEC s, and investigators.  
● An investigator who receives an investigator safety report describing a n SAE 
or other specific safety information ( for example , summary or listing of SAEs) 
from the sponsor will review and then file it along with the Investigator’s 
Broc hure and will notify the IRB/IEC, if appropriate according to local 
requirements.  
  
Approved on 17 Aug 2021 GMT
C O N FI D E N TI A L  J 2 T -M C -K G B G (b) 
 5 6    
 
 
 
 
 
 
 
 
 
 
  
  
  
  
  
  
 
 
 
 
  
 
 
  
  
  
 
 
  
 
 
 
  
 
 
 
 
 
A p pr o ve d o n 1 7 A u g 2 0 2 1 G M T C CI 
C CI 
C O N FI D E N TI A L  J 2 T -M C -K G B G (b) 
 5 7   
 
 
  
  
 
 
 
 
 
 
  
 
 
 
 
  
  
    
 
  
  
  
 
  
  
  
 
   
  
     
  
 
  
  
  
  
   
 
 
A p pr o ve d o n 1 7 A u g 2 0 2 1 G M T C CI C CI 
C O N FI D E N TI A L  J 2 T -M C -K G B G (b) 
 5 8    
  
  
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
A p pr o ve d o n 1 7 A u g 2 0 2 1 G M T C CI 
C O N FI D E N TI A L  J 2 T -M C -K G B G (b) 
 5 9   
  
 
  
A p pr o ve d o n 1 7 A u g 2 0 2 1 G M T C CI 
C CI 
C O N FI D E N TI A L  J 2 T -M C -K G B G (b) 
 6 0    
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
A p pr o ve d o n 1 7 A u g 2 0 2 1 G M T C CI 
C O N FI D E N TI A L  J 2 T -M C -K G B G (b) 
 6 1    
 
 
 
 
 
 
 
  
  
  
  
  
  
      
      
      
      
      
  
  
  
 
  
  
   
      
      
  
      
      
      
      
      
A p pr o ve d o n 1 7 A u g 2 0 2 1 G M T C CI C CI 
C O N FI D E N TI A L  J 2 T -M C -K G B G (b) 
 6 2          
  
          
            
  
          
       
      
           
           
   
 
  
      
      
 
 
 
 
 
 
  
A p pr o ve d o n 1 7 A u g 2 0 2 1 G M T C CI 
C O N FI D E N TI A L  J 2 T -M C -K G B G (b) 
 6 3   
 
 
 
    
 
 
 
  
 
A p pr o ve d o n 1 7 A u g 2 0 2 1 G M T C CI 
C O N FI D E N TI A L  J 2 T -M C -K G B G (b) 
 6 4   
  
 
  
 
 
   
 
 
   
 
   
 
 
 
 
 
 
 
  
   
 
  
  
 
 
 
  
 
  
 
  
 
 
 
A p pr o ve d o n 1 7 A u g 2 0 2 1 G M T C CI 
CONFIDENTIAL  J2T-MC-KGBG (b) 
 65 10.8. Appendix 8: Medical Device Adverse Events (AEs), Adverse Device 
Effects (ADEs), Serious Adverse Events (SAEs) and Device Deficiencies : 
Definition and Procedures for Recording, Evaluating, Follow -up, and 
Reporting  
Refer to  Appendix 3 (Section  10.3) for defin itions and procedures for recording, evaluating, 
follow -up, and reporting of all events.  
  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 66 10.9. Appendix 9: Abbreviations  
Term  Definition  
AD atopic dermatitis  
ADA  antidrug antibody  
ADE  adverse device effect  
AE adverse event  
AI autoinjecto r 
ALP alkaline phosphatase  
ALT alanine aminotransferase  
AST aspartate aminotransferase  
AUC  area under the concentration versus time curve  
AUC(0 -∞)  area under the concentration versus time curve from time zero to infinity  
AUC([ADDRESS_1044325]) area under the concentration versus time curve from time zero to time t, where t is the 
last time  point with a measurable concentration  
CI confidence interval  
Cmax  maximum observed drug concentration  
complaint  A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.  
compliance  Adherence to all study -related, good clinical practice (GCP), and applicable regu latory 
requirements.  
CRF case report form  
CRP  clinical research physician:  Individual responsible for the medical conduct of the 
study.  Responsibilities of the CRP may be performed by a physician,  clinical research 
scientist, global safety physician , or other medical officer.  
CRU clinical research unit  
CV coefficient of variation  
device deficiencies  equivalent  to product complaint  
ECG  electrocardiogram  
enroll  The act of assigning a participant  to a treatment.  Participants  who are enrolled in the 
study are those who have been assigned to a treatment.  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 [ADDRESS_1044326]  
ISR injection -site reaction  
informed consent  A process by [CONTACT_9444] a participant  voluntarily confirms his or her willingness to 
participate in a particular study, after having been informed of all aspects of the study 
that are relevant to the participant’s  decision to participate.  Informed consent is 
documented by [CONTACT_3553] a written, signed , and dated informed consent form . 
investigational 
product  A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further info rmation about the authorized form.  
IWRS  interactive web -response system  
participant  Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as a recipi[INVESTIGATOR_10930] a control  
PFS-NSD  pre-filled syringe  with n eedle safety device  
PK pharmacokinetics  
PT preferred term  
SADE  serious adverse device effect  
SAE serious adverse event  
SC subcutaneous  
screen  The act of determining if an individual meets minimum requirements to become part 
of a pool of potential candidates for participation in a clinical study.  
SoA Schedule of Activities  
TB tuberculosis  
TBL total bilirubin  
TE-ADA  treatment -emergent antidrug antibod y 
tmax  time of C max 
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 [ADDRESS_1044327] upper limit of normal  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 69 10.10.  Appendix 1 0: Protocol Amendment History  
The Protocol Amendment Summary of Changes for the current amendment is located directly 
before the Table of Contents (TOC).  
Amendment [ a]: (19 May 2021 ) 
 
Overall Rationale for the Amendment  
This amendment incorporates changes to provide clarification on pregnancy testing, concomitant 
medications, and the definition of postmenopausal female.  
Section # a nd Name  [CONTACT_11029]  
1.3. Schedule of 
Activities (SoA)  Pregnancy test was revised to be 
required for females of 
childbearing potential only.  SoA revised to align with 
Section 10.[ADDRESS_1044328] vis it. Language was revised for 
clarity.  
10.4. Appendix 4: 
Contraceptive Guidance 
and Collection of 
Pregnancy Information  Additional text was added to 
clarify the definition of 
postmenopausal female . Definition of postmenopausal 
female clarified.  
10.4. App endix 4: 
Contraceptive Guidance 
and Collection of 
Pregnancy Information  Pregnancy test was revised to be 
required for females of 
childbearing potential only.  Section 10.4 Appendix 4 
revised to align with Section 
10.2 Appendix 2.  
Approved on 17 Aug 2021 GMT
CONFIDENTIAL  J2T-MC-KGBG (b) 
 70 11. References  
Sampson HA, Mu ñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and  
management of anaphylaxis. Summary report. Second National Institute of Allergy and  
Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin  Immunol . 
2006;117 :391-398. doi.org/10.1016/j.jaci.2005.12.1303  
Williamson  A, Hoggart B. Pain: a review of three commonly used pain rating scales. J Clin 
Nurs . 2005;14(7) :798-804. doi.org/10.1111/j.1365 -2702.2005.[ZIP_CODE].x  
Zhu R, Zheng Y, Dirks NL, et al. Model -based clinical pharmacology profiling and exposure -
response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate -
to-severe asthma. Pulm Pharmacol Ther . 2017;46:88 -98. doi.org/10.1016/j.pupt.2017.08.010  
 
Approved on 17 Aug 2021 GMT
Si g nat ure Pa ge f or V V- C LI N- 0 0 2 5 8 2 v 1. 0 
Si g nat ure Pa ge f or V V- C LI N- 0 0 2 5 8 2 v 1. 0 A p pr o val 
or 
1 7- A u g- 2 0 2 1 0 2: 4 5: 0 6 G M T + 0 0 0 0 
A p pr o val 
n
1 7- A u g- 2 0 2 1 1 9: 0 0: 4 5 G M T + 0 0 0 0 
A p pr o ve d o n 1 7 A u g 2 0 2 1 G M T P P D P P D 